MedTrace Logo

Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)

NCT01380184 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-04-19

Study results available
· View outcomes & findings →

Summary

Part 1 of the study will assess the pharmacokinetics, safety, and tolerability of ridaforolimus (MK-8669) after administration of single and multiple 40 mg doses in Chinese participants with advanced cancer. Part 2 of the study is optional; participants can continue to receive the study treatment in a weekly regimen of daily oral doses of ridaforolimus 40 mg for five consecutive days followed by two days off-treatment.

Conditions

  • Cancer, Advanced

Interventions

DRUG

ridaforolimus

4 enteric-coated tablets, each containing 10 mg ridaforolimus, orally (total daily dose: 40 mg)

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-05
Primary Completion
2011-10-20
Completion
2012-04-05

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01380184 on ClinicalTrials.gov